Tekla Life Sciences Investors Stock Forecast, Price & News

Wall Street analysts have given Tekla Life Sciences Investors a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Tekla Life Sciences Investors wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Tekla Life Sciences Investors saw a decrease in short interest in the month of August. As of August 31st, there was short interest totaling 26,900 shares, a decrease of 40.5% from the August 15th total of 45,200 shares. Based on an average trading volume of 67,600 shares, the short-interest ratio is currently 0.4 days.
View Tekla Life Sciences Investors' Short Interest.

Tekla Life Sciences Investors' stock was trading at $14.85 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, HQL stock has increased by 43.6% and is now trading at $21.32.
View which stocks have been most impacted by COVID-19.

Tekla Life Sciences Investors declared a quarterly dividend on Wednesday, August 18th. Shareholders of record on Friday, August 27th will be given a dividend of $0.43 per share on Thursday, September 30th. This represents a $1.72 dividend on an annualized basis and a yield of 8.07%. The ex-dividend date is Thursday, August 26th. This is an increase from Tekla Life Sciences Investors's previous quarterly dividend of $0.41.
View Tekla Life Sciences Investors' dividend history.

Tekla Life Sciences Investors pays an annual dividend of $1.67 per share and currently has a dividend yield of 7.68%. HQL has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer.
View Tekla Life Sciences Investors' dividend history.

Some companies that are related to Tekla Life Sciences Investors include PIMCO Corporate & Income Opportunity Fund (PTY), WisdomTree Emerging Markets High Dividend Fund (DEM), Hercules Capital (HTGC), Goldman Sachs BDC (GSBD), Royce Value Trust (RVT), Liberty All-Star Equity Fund (USA), Tri-Continental (TY), The Gabelli Equity Trust (GAB), iShares MSCI Australia ETF (EWA), Boulder Growth & Income Fund (BIF), Nuveen Nasdaq 100 Dynamic Overwrite Fund (QQQX), Tekla Healthcare Investors (HQH), Central Securities (CET), General American Investors (GAM) and AllianceBernstein Global High Income Fund (AWF).
View all of HQL's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Tekla Life Sciences Investors investors own include NVIDIA (NVDA), Energy Transfer (ET), QUALCOMM (QCOM), AT&T (T), Enbridge (ENB), International Business Machines (IBM), Kinder Morgan (KMI), Main Street Capital (MAIN), Pfizer (PFE) and Weyerhaeuser (WY).

Tekla Life Sciences Investors trades on the New York Stock Exchange (NYSE) under the ticker symbol "HQL."

Tekla Life Sciences Investors' stock is owned by many different retail and institutional investors. Top institutional shareholders include Advisors Asset Management Inc. (1.80%), Morgan Stanley (1.74%), Morgan Stanley (1.74%), Wells Fargo & Company MN (1.35%), Matisse Capital (0.68%) and Advisor Group Holdings Inc. (0.55%).
View institutional ownership trends for Tekla Life Sciences Investors.

HQL stock was sold by a variety of institutional investors in the last quarter, including 1832 Asset Management L.P., 1832 Asset Management L.P., Matisse Capital, Wells Fargo & Company MN, 1607 Capital Partners LLC, Citigroup Inc., Invesco Ltd., and Advisor Group Holdings Inc..
View insider buying and selling activity for Tekla Life Sciences Investors or view top insider-selling stocks.

HQL stock was bought by a variety of institutional investors in the last quarter, including Stephens Inc. AR, Shaker Financial Services LLC, Morgan Stanley, Morgan Stanley, Advisors Asset Management Inc., Kingsview Wealth Management LLC, Cambridge Investment Research Advisors Inc., and Mid Atlantic Financial Management Inc. ADV.
View insider buying and selling activity for Tekla Life Sciences Investors or or view top insider-buying stocks.

Shares of HQL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of HQL stock can currently be purchased for approximately $21.32.

Tekla Life Sciences Investors has a market capitalization of $517.63 million.

The official website for Tekla Life Sciences Investors is www.teklacap.com.

Tekla Life Sciences Investors is headquartered at 2 LIBERTY SQUARE 9TH FLOOR, BOSTON MA, 02109.

Tekla Life Sciences Investors' mailing address is 2 LIBERTY SQUARE 9TH FLOOR, BOSTON MA, 02109. The company can be reached via phone at (617) 772-8500 or via email at [email protected].